Chicago, IL (August 1, 2019) – Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, announced today the acquisition of Collagen Matrix, Inc. (“CMI” or the “Company”). Headquartered in Oakland, New Jersey, CMI is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration across orthopedic, sports medicine, dental, and neurosurgery end markets.
Gerard Moufflet, Linden Operating Partner, stated, “the CMI team’s unique understanding of collagen-based technologies along with their commitment to innovation and quality manufacturing make CMI stand out as a leading biomaterials developer and manufacturer.” Following the transaction, Mr. Moufflet has joined the Board of Directors of CMI. Brian Miller, Managing Partner of Linden, added, “the CMI investment represents Linden’s subsector and Operating Partner driven strategy, highlighting our ongoing focus on medical products, contract and private label manufacturing, and the dental and orthopedic sectors.”
William Blair served as exclusive financial advisor and Kirkland & Ellis LLP served as legal advisor to Linden. Robert W. Baird and Piper Jaffray served as financial advisors and Ropes & Gray LLP served as legal advisor to CMI. Golub Capital and Northwestern Mutual provided debt financing for the transaction.
About Collagen Matrix, Inc.
Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration. Founded in 1997, Collagen Matrix is headquartered in Oakland, New Jersey and develops proprietary products that are sold to OEM customers on either a contract or private label basis across orthopedic, sports medicine, dental, and neurosurgery end markets. The company also offers partnership opportunities including distribution, contract product development, and contract manufacturing services. For more information, please visit www.collagenmatrix.com.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry. Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.
SOURCE: Lindenllc, 1st August 2019